Ipratropium Bromide

Therapeutic Segment Bronchodilator

CAS No. 22254-24-6

Regulatory Filing USDMF, CEP

Development Status DMF Filed

Molecule Type Small Molecule

Enquire Now

Mechanism of Action

Ipratropium bromide is an anticholinergic agent which appears to inhibit vagally-mediated reflexes by antagonizing the action of acetylcholine released at the neuromuscular junctions in the lung. Anticholinergics prevent the increases in intracellular concentration of Ca++ which is caused by interaction of acetylcholine with the muscarinic receptors on bronchial smooth muscle.

Disclaimer: No information in this Catalog – including any reference to any product or service – constitutes an offer for sale or be constructed as representing an offer for sale. Products protected under valid patents are not offered or supplied for commercial use. However, under Bolar Provision the research quantities of such products may be offered for the purpose of regulatory submissions, wherever such regulatory exemptions exist. The buyers should make their independent evaluation of patent scenario for their respective markets and will be responsible for all patent related liabilities.